Signaturefd LLC Increases Position in Gilead Sciences, Inc. $GILD

Signaturefd LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,612 shares of the biopharmaceutical company’s stock after purchasing an additional 1,274 shares during the period. Signaturefd LLC’s holdings in Gilead Sciences were worth $2,729,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the first quarter valued at approximately $25,000. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the first quarter valued at about $29,000. Colonial Trust Advisors increased its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Finally, Core Alternative Capital boosted its position in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.0%

Gilead Sciences stock opened at $112.10 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $82.82 and a one year high of $121.83. The stock has a 50-day moving average of $114.41 and a two-hundred day moving average of $109.92. The stock has a market cap of $139.09 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Ratings Changes

A number of research analysts recently weighed in on GILD shares. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares of the company’s stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,390,030 over the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.